U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07384390) titled 'TH-CAR-027 for Grade 4 Gliomas' on Jan. 26.
Brief Summary: This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive grade 4 glioma
Study Start Date: Jan. 30
Study Type: INTERVENTIONAL
Condition:
R/R Grade 4 Glioma
Intervention:
DRUG: TH-CART-027
Multiple-dosing, intratumoral and/or intraventricular infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine
Information provided by (Responsible Party...